Swiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Sensitivity analyses showed that cost savings on subcutaneous formulation ranged from RM3715 to RM11408 to the Ministry of Health. Overall, subcutaneous trastuzumab is estimated to be cost-saving from ...

About Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous (SC)) Phesgo is a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered ...

NEW YORK – Strong uptake of Roche's Phesgo, a subcutaneous formulation of Herceptin (trastuzumab) and Perjeta (pertuzumab), was a key driver of sales growth for the company in the first quarter of ...

A subcutaneous injectable form of nivolumab is available to treat melanoma, non-small cell lung cancer, renal cell cancer, and many other cancers.

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...

Celltrion advances its subcutaneous biosimilar portfolio with a new Herzuma trial, following the success of Remsima SC and recent European approvals. Herceptin has been a cornerstone breast cancer ...